KTTA earnings analysis
What we found in KTTA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The extracted 10-Q text does not include the income statement, balance sheet, cash flow statement, MD&A, or segment disclosures, so revenue, margins, EPS, liquidity, and cash-flow trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, and no material internal-control changes were reported during the six months ended June 30, 2026. The company reported no material changes to the risk factors in its December 31, 2025 Form 10-K.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure Controls Deemed Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
- No Material Control Changes
- The company reported no changes in internal control over financial reporting during the six months ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Existing Risk Factors Remain
- The filing states there were no material changes to the risk factors in the December 31, 2025 Form 10-K filed on March 30, 2026; the previously disclosed risks therefore remain applicable.
- Limitations of Internal Controls
- Management acknowledges that control systems provide only reasonable, not absolute, assurance and may not prevent or detect all errors or fraud.
What they said about what is next.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q text; guidance was not provided.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 15, 2026
- Pasithea Therapeutics Corp. reported a net loss of $2.87 million for Q1 2026, which is an improvement compared to a net loss of $3.56 million in Q1 2025, indicating a 19.5% reduction in losses year-over-year. Research…
- 10-K · March 30, 2026
- KTTA is a clinical-stage biotech focused on PAS-004, a macrocyclic MEK1/2 inhibitor aimed initially at NF1-PN and MAPK-driven tumors. Early clinical data through a December 26, 2025 cut-off show 34 patients dosed across…
- 10-Q · May 15, 2025
- Pasithea reported a smaller net loss of $3,563,238 for Q1 2025 (EPS $(1.61)) versus a net loss of $3,860,840 in Q1 2024 (EPS $(3.70)), driven by lower operating expenses and a non-cash $76,867 favorable change in…
- 10-Q · November 13, 2024
- Pasithea Therapeutics reported a Q3 GAAP net loss of $2,999,834 (loss per share $2.87) compared with a loss of $3,612,590 in Q3 2023, driven by lower G&A but continued R&D spend. Cash declined to $9.36M at September 30,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing KTTA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever